ScreenerHero

ABVX ABIVAX Société Anonyme

EPA · FR · Healthcare · Biotechnology · abivax.com
80.90EUR-3.11%Mkt Cap: 7.67B $P/E: —

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap7.67B USD
Enterprise Value6.81B USD
Revenue (TTM)5.07M USD
Gross Profit5.07M USD
Net Income (TTM)-365.33M USD
Revenue/Share0.06 EUR
Last Price80.90 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees98
CountryFR
SectorHealthcare
IndustryBiotechnology
ISINFR0012333284
Valuation
P/E (Trailing)—
P/E (Forward)-28.77
PEG—
EV/EBITDA-21.48
EV/Revenue1341.81
P/S1561.09
P/B18.20
EPS (TTM)-5.21
EPS (Forward)-2.90
52W Range
60.4526% of range139.00
52W High139.00 EUR
52W Low60.45 EUR
Profitability
Gross Margin100.00%
Oper. Margin-8617.93%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-73.84%
ROA-57.52%
Growth
Revenue Growth-6.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-175.14M USD
CapEx (TTM)154.35K USD
FCF Margin-2697.05%
FCF Yield-1.78%
Net Debt-436.06M USD
Net Debt/EBITDA1.38
Balance Sheet
Debt/Equity0.00
Current Ratio5.96
Quick Ratio5.79
Book Value/Sh4.59 EUR
Cash/Share5.04 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 EUR
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.6 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)135.01 EUR
Upside (mean)+66.9%
Target Range70.00 EUR – 180.00 EUR
70.00+66.9% to mean180.00
# Analysts7
Ownership
Shares Out.87.27M
Float69.03M
Insiders4.17%
Institutions50.35%
Technical
SMA 5099.07 (-18.3%)
SMA 200101.82 (-20.5%)
Beta-0.25
S&P 52W Chg14.58%
Avg Vol (30d)156.11K
Avg Vol (10d)139.96K
Technical Indicators
RSI (14)35.1
MACD-4.7128
MACD Signal-4.5463
MACD Hist.-0.1665
BB Upper105.38 EUR
BB Middle90.89 EUR
BB Lower76.39 EUR
BB Width31.90%
ATR (14)3.810 EUR
Vol Ratio (20d)0.91x